-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NFS-02 in Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NFS-02 in Leber's Hereditary Optic Neuropathy...
-
Product Insights
Optic Nerve Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Nerve Injury - Drugs In Development, 2023’, provides an overview of the Optic Nerve Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drugs In Development, 2023’, provides an overview of the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drug Details: NFS-02 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NFS-01
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NFS-01 Drug Details NFS-01 is under development for the treatment of Leber hereditary optic...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leber’s hereditary optic neuropathy (LHON) symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer-treating drugs, stress-related chemicals, some antibiotics, and cyanogens. The LHON pipeline drugs market research report provides an analysis of the LHON drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history,...